Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.75 |
| ▸ | GSPT1 | P15170 | 11/20 | 0.75 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.75 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.75 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413700 | 0.93 | CRBN (0.86) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240018 | 0.93 | CRBN (0.78) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240145 | 0.93 | CRBN (0.88) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240228 | 0.91 | CRBN (0.70) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240149 | 0.90 | CRBN (0.67) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240142 | 0.90 | CRBN (0.67) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23239950 | 0.89 | CRBN (0.67) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240162 | 0.88 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240026 | 0.88 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL23240028 | 0.88 | CRBN (0.70) | CRBNGSPT1DDB1IKZF3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2022256623-A1 | E3 LIGASE FUSION PROTEINS FOR PROXIMITY DETECTION | MONTE ROSA THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CRBN 524/4885GSPT1 1795/4885DDB1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.